Antigen News and Research

RSS

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

North Shore-LIJ seeks patients with early-stage prostate cancer to participate in Phase I study

The North Shore-LIJ Health System Department of Radiation Medicine announced today it is seeking patients with early-stage prostate cancer to participate in a Phase I Research study.

29 Jan 2011

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.

28 Jan 2011

Scientist identifies polymorphism that raises risk of poor outcomes in preterm infants

Researchers at Cincinnati Children's Hospital Medical Center have identified biomarkers of poor outcomes in preterm infants that may help identify new approaches to prevention.

28 Jan 2011

Pfenex receives $3.1 million SAIC sub-contract to develop malaria antigen

Pfenex today announced that Science Applications International Corporation has awarded Pfenex a sub-contract valued at $3.1 million to help develop a robust, scalable, cGMP ready production process for large scale production of full length Circumsporozoite protein from Plasmodium falciparum.

27 Jan 2011

FDA issues Complete Response letter for Avodart sNDA for reduction of prostate cancer risk

GlaxoSmithKline (GSK) today announced that the Company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the supplemental New Drug Application (sNDA) for Avodart® (dutasteride) for reducing the risk of prostate cancer in men at increased risk for the disease, defined as those who have had a prior negative biopsy due to clinical concern and have an elevated serum prostate-specific antigen (PSA).

27 Jan 2011

Diamyd Medical reports first quarter group total net sales of MSEK 144.5

Diamyd completed screening for US Phase III study in type 1 diabetes. The screening of patients for the US Phase III study, DiaPrevent, was completed, ending the recruitment campaign. More than 310 recently diagnosed type 1 diabetes patients between 10 and 20 years of age had, at the completion of screening, been enrolled in the study and received their first injection of the antigen-based therapy Diamyd® or placebo.

25 Jan 2011

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Agenus Inc. today announced it has entered into a research agreement with Memorial Sloan-Kettering Cancer Center (MSKCC) using Agenus' proprietary cancer vaccine technology.

24 Jan 2011

Researchers map complex choreography used by immune system's T cells to recognize pathogens

Researchers have for the first time mapped the complex choreography used by the immune system's T cells to recognize pathogens while avoiding attacks on the body's own cells.

21 Jan 2011

OriGene releases 1,500 mouse monoclonal antibodies

OriGene Technologies, Inc. has recently achieved a significant milestone in its quest for developing an assay for every human protein through the release of 1,500 mouse monoclonal antibodies under the TrueMAB brand. Each TrueMAB antibody is specifically developed with full-length human proteins produced in HEK293T cells and validated for critical research and diagnostic needs requiring improved antibody sensitivity and specificity.

21 Jan 2011

National Jewish Health issued method patent for desensitizing B cells

National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants.

19 Jan 2011

Vaccine to prevent MRSA infections after bone and joint surgery

University of Rochester Medical Center orthopaedic scientists are a step closer to developing a vaccine to prevent life-threatening methicillin-resistant staphylococcus aureus (MRSA) infections following bone and joint surgery.

18 Jan 2011

Scientists demonstrate mechanism that explains why PSA levels promote prostate cancer

Researchers at the Duke Cancer Institute who have been studying prostate cancer cells for decades now think they know why PSA levels reflect cancer progression.

14 Jan 2011

T.A. Sciences receives US patent for TA-65 to tackle aging process

Telomerase Activation Sciences, today announced the issuance of U.S. Patent No. 7,846,904 to the Geron Corporation. The patent covers the use of certain compounds to upregulate telomerase expression in cells.

14 Jan 2011

New research paper reveals key lessons about origins of 2009 H1N1 pandemic

How Swine Flu Overturned the Understanding of Pandemic Outbreaks. As H1N1 'Swine Flu' returns to the national headlines a new research paper reveals the key lessons about the origins of the 2009 pandemic. The paper, published today in BioEssays, reveals how the pandemic challenges the traditional understanding of 'antigenic shift', given that the virus emerged from an existing influenza subtype.

13 Jan 2011

Micromet, MedImmune initiate MT111 Phase 1 trial in patients with advanced gastrointestinal cancer

MedImmune, the global biologics unit of AstraZeneca PLC and Micromet, today announced the initiation of a Phase 1 trial of MEDI-565 in patients with advanced gastrointestinal cancers. MEDI-565 is a BiTE antibody designed to direct a patient's T cells, the body's most potent killer cells, against cancer cells that express carcinoembryonic antigen.

13 Jan 2011

Negative aspects of prostate cancer screening acceptable

The negative aspects of screening for prostate cancer may be acceptable, since screening halves mortality from the disease. This is the conclusion of a thesis presented at the University of Gothenburg, Sweden.

12 Jan 2011

PLoS Neglected Tropical Diseases features Inovio’s Chikungunya DNA vaccine

Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper highlighting positive results from Inovio's multi-antigen Chikungunya virus (CHIKV) DNA vaccine in PLoS Neglected Tropical Diseases.

12 Jan 2011

Study shows delivering cancer drug in hydrophobic nanoparticle is a safe and effective prostate cancer therapy

Researchers at MIT and Brigham and Women's Hospital have shown that they can deliver the cancer drug cisplatin much more effectively and safely in a form that has been encapsulated in a nanoparticle targeted to prostate tumor cells and is activated once it reaches its target.

12 Jan 2011

Eric Lancaster receives NORD grant to study stiff-person syndrome

The National Organization for Rare Disorders has awarded a research grant for the study of stiff-person syndrome, a rare acquired neurological disorder, to Eric Lancaster, MD, PhD of the University of Pennsylvania.

11 Jan 2011

Antigen News and Research

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

North Shore-LIJ seeks patients with early-stage prostate cancer to participate in Phase I study

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

Scientist identifies polymorphism that raises risk of poor outcomes in preterm infants

Pfenex receives $3.1 million SAIC sub-contract to develop malaria antigen

FDA issues Complete Response letter for Avodart sNDA for reduction of prostate cancer risk

Diamyd Medical reports first quarter group total net sales of MSEK 144.5

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Researchers map complex choreography used by immune system's T cells to recognize pathogens

OriGene releases 1,500 mouse monoclonal antibodies

National Jewish Health issued method patent for desensitizing B cells

Vaccine to prevent MRSA infections after bone and joint surgery

Scientists demonstrate mechanism that explains why PSA levels promote prostate cancer

T.A. Sciences receives US patent for TA-65 to tackle aging process

New research paper reveals key lessons about origins of 2009 H1N1 pandemic

Micromet, MedImmune initiate MT111 Phase 1 trial in patients with advanced gastrointestinal cancer

Negative aspects of prostate cancer screening acceptable

PLoS Neglected Tropical Diseases features Inovio’s Chikungunya DNA vaccine

Study shows delivering cancer drug in hydrophobic nanoparticle is a safe and effective prostate cancer therapy

Eric Lancaster receives NORD grant to study stiff-person syndrome

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics